Our study provides a new insight in which CYP3A-mediated drug interaction as a possible contributor for the increased effectiveness of the PZQ + DHP combination therapy than PZQ monotherapy for the treatment and control of schistosomiasis. The gene discussed is CYP3A4; the disease is schistosomiasis.